ArticleDiscover oncology2026
Apolipoprotein B is considered a potential therapeutic drug target for the treatment of AML.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAcute myeloid leukemia (AML) faces significant challenges in the development of novel therapeutic strategies due to drug resistance and disease relapse. Therefore, this study aims to identify new therapeutic targets for AML using a drug-target Mendelian randomization approach.
methodsSummary-level data on low-density lipoprotein (LDL)-related traits were obtained from the GWAS data available on the IEU Open GWAS platform, and AML-associated genetic data were sourced from the GWAS Catalog. Seven genes involved in LDL metabolism were selected as potential drug targets: Apolipoprotein A4 (APOA4), Apolipoprotein B (APOB), Apolipoprotein C1 (APOC1), Apolipoprotein E (APOE), Cholesteryl Ester Transfer Protein (CETP), LDL Receptor (LDLR), and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). The inverse-variance weighted (IVW) method was used as the primary analytical approach, with supplementary analyses conducted using MR-Egger regression, weighted median, simple mode, and weighted mode methods to validate the findings.
results1. Drug-target Mendelian randomization analysis revealed that lowering LDL levels by targeting and inhibiting APOB may increase the risk of AML, with rs13392272 identified as a potential functional locus in this process. 2. Further validation showed that targeting and inhibiting APOB to reduce its own levels may also increase the risk of AML, with rs693 considered a potential functional locus involved in this effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.